Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.60 |
| ▸ | SLC34A1 | Q06495 | 7/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | SMO | Q99835 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299115 | 0.87 | AR (0.60) | ARSLC34A1P2RX7SMO | |
| SCHEMBL4233511 | 0.85 | AR (0.70) | ARSLC34A1P2RX7SMO | |
| SCHEMBL4239307 | 0.84 | AR (0.60) | ARSLC34A1P2RX7SMO | |
| SCHEMBL4242393 | 0.84 | AR (0.57) | ARSLC34A1P2RX7SMOMEN1 | |
| SCHEMBL4296543 | 0.84 | AR (0.65) | AR | |
| SCHEMBL4230109 | 0.83 | AR (0.56) | ARSLC34A1P2RX7SMO | |
| SCHEMBL4233150 | 0.83 | AR (0.60) | ARSLC34A1SMOMEN1KMT2A | |
| SCHEMBL4239402 | 0.82 | AR (0.55) | ARSLC34A1P2RX7SMO | |
| SCHEMBL4303853 | 0.82 | AR (0.60) | ARSLC34A1P2RX7SMO | |
| SCHEMBL4301400 | 0.81 | AR (0.54) | ARSLC34A1P2RX7SMOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | AR 622/4885SLC34A1 1375/4885P2RX7 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.